Trial design will either be 6/12 months. With known data to substantiate a shorter trial it may very well be a 6 month design. We'll know more when recruitment starts.

Aricept was stopped after only 6 months. So yes early approval is quite possible with excellent results.

No AD not specifically, I took it as he meant the Alz P2/3 study as it was the next bullet point. Rett and Parkinsons are both 12 week trials so yes it could be one or more of any.

At Noble Dr Missling reported readout for P2/3 Alz 6-12 month study would come at the end of 2017 or start of 2018. Study does need to start very soon to make 2017 though.

Sobering Alzheimers report.

https://www.yahoo.com/finance/news/death-rate-alzheimers-disease-increased-204100924.html

Topline B-UP data including a B-OM update are both for unmet medical need and due first giving share price a nice boost. P is in a more crowded space then it was a couple years ago but any sub par news would take focus off B and not be viewed good by the poopoo'ers. Luckily P2B for my money is less risky since it's dove tailing off the P2A 200mg data which saw greater improvement in that arm. I believe this ongoing dose escalation study will be seen as very good and kick this thing onto the Nasdaq.

Your all alone here and have absolutely no bearing on which way this market moves.

Exactly. This run is heading straight up to multiple data releases.

Plowed through .97 picked up 2959, it was way too easy. Come on fellow investors it's like taking candy away from babies.

One thing is to not think of Brilacidin as strictly a antibiotic but a defense protein mimetic. Antibiotics need allowed through the bacterial cell wall to kill it. Brilacidin's MOA works faster by simply blowing a hole through the cell wall, this method has very little chance ever of developing resistance.

https://en.wikipedia.org/wiki/Brilacidin

Good point. Less side effects also comes into play.

What he said in the first 3 paragraphs was spot on. I will say if Norchi doesn't have good news by 1 June stock could retrace another 50%.

Glad to see you posting here once again. Yes appreciate the posters of honest character not characters.

I believe we have all that we need till Topline release. If Leo was to update now bashers would say it was insignificant.

Exactly. Now some are suggesting to flip..Bahaha. I'm holding as were close to several major catalysts now.

Actually back on the 12th.69-.699 then more yesterday and today. My roth is well invested and I'm over 59 1/2 so bring it on.

Bought yesterday and now 1290@.88. I see odds in investors favor.

And we all know that turned out. Dud don't be on the wrong side of it.

Don't leave out ctix's menu of indications...I may recommend you the B-UP as an appetizer.

You conveniently overlooked this part of that statement:
"Based on results observed in the first two cohorts of patients who completed treatment, Brilacidin showed strong signs of efficacy while being well-tolerated, reinforcing its potential to become a novel, non-corticosteroid, non-biologic anti-inflammatory drug candidate".

Leo was pointing out that a gel or foam would produce a much longer therapeutic dwell period. The new formulation would make it advantageous for the home user to apply as well as cut the times a user would need to reapply.

Put more in my favorite uncle Leo play, still up 45% here. Avxl will blast off soon no worries here.

Well captain obvious, ask is .87.

Agree. Leo's in control now.

Manipulation holds no bounds, Believe me.

I also believe stock will keep moving up going into July conference. Both trials are late stage for unmet needs so I believe with further compelling data we would see heavy buying as the market catches on. BTD this year for B-OM would be a moon ticket. Fact is we have many moon shots here.

Lets say it's a third party screw up, where's the accountability and how many months back has Norchi known of the CE mark slip. He's done a good job of keeping share holders in the dark.

CFO gained 35000.. were these options tied to a financial deal.

Could be, Missling and company sought approval hard knowing it would add much more leverage.

Your just pulling numbers from a dark place..

Kentucky123

http://www.anavex.com/anavex-compound-to-be-tested-in-biogen-neurological-protection-model/

Pharmacodynamics study relationship between drug concentrations and effect on organs.

The internet is smart regarding science. Taking time to do your own due diligence would be wise.

Yes. Could be her in position involving regulatory matters was no longer required so she moved on.

Clearly the company has a plan going forward that for some reason or another just did not include that employee. King Arthur the man with the plan is still making science decisions. Possibly she didn't have the companies best interest at heart.

You'll soon be in the rear view mirror.lol

I would include this flushing period during sleep also included damaged cells that the brain detected as harmful.

I recently watched a PBS program and in this program scientists see a very possible linking of Alzheimer's to insomnia. They say the act of deep sleep is a period the brain uses to flush out spent dead cells to keep damaging toxins from building up.

These are elderly people some in advanced age and with underlying health problems. That said many would regard a 21.9% dropout rate in a two+ years long Alzheimer's trial that is still ongoing a complete success. This trial has turned into a at home therapy in which patients have been approved to keep taking their medicine because it works for them.

Also this:

"Second, the Company will be presenting topline findings from the Brilacidin-UP/UPS trial as well as additional interim data from its Phase 2 trial of Brilacidin for Oral Mucositis at Drug Discovery and Therapy World Congress 2017, to be held July 10 – 13, 2017, in Boston. More details to come."

Even though third and final cohort is just finishing up, Cellceutix's signal to present at Drug Discovery and Therapy World Congress 2017 is very bullish signal concerning UP/UPS topline data. Additionally saying B-OM interim results will also be presented really helps further bolster the furthering range of diseases Brilacidin could be effective against.

Yes it is a "wonderful Buying Opportunity". Thanks for your strong ctix support.

Good question for the CRO. I believe they based trial speed on efficiency saw in P2A. CRO didn't take account of competing trials. It is what it is but I'm still betting on 3rd quarter, who knows maybe one of the other trials fails early.

They reassessed and added sites to make the 3rd quarter goal. Some of the competing trials must pay their volunteers well:)